Insights

Including Functional Claim Language Helped Save Pozen’s VIMOVO® Patents, PTAB Litigation Blog

Visit the Jones Day PTAB Litigation Blog.

On February 28, 2017, the PTAB held that the petitioner Lupin had not shown that the challenged claims in two of Pozen’s patents were invalid (IPR2015-01773 and IPR2015-01775).  These cases show the advantage of using functional language in a product or process claim.

The patents at issue are U.S. Patent Nos. 8,858,996 and 8,865,190. Both patents cover VIMOVO® (commercially sold by Horizon Pharma). The ’996 patent claims a pharmaceutical composition that provides for the coordinated release of esomeprazole (a well known proton pump inhibitor) and naproxen (a non-steroidal anti-inflammatory drug (NSAID) well known for controlling pain), such that there is a reduced likelihood of naproxen causing unwanted gastrointestinal side effects when administered as a treatment for pain. The ’190 claims are directed to processes for preparing the pharmaceutical compositions

Read the full article at ptablitigationblog.com.

We use cookies to deliver our online services. Details of the cookies and other tracking technologies we use and instructions on how to disable them are set out in our Cookies Policy. By using this website you consent to our use of cookies.